Glenmark Pharmaceuticals Ltd

The company said the decision to start advanced injectable therapy is often delayed in many patients due to cost and complexity. With GLIPIQ, Glenmark aims to improve affordability and enable earlier treatment initiation across a broader patient population. GLIPIQ has been approved by the Central Drugs Standard Control Organization (CDSCO) following a multicentre, randomised, comparative, active-controlled, open-label Phase III clinical study conducted in India. The study demonstrated favourable efficacy and safety outcomes in Indian patients with Type 2 diabetes. The drug is available in both vial and pre-filled pen formulations. The vial-based version, supported by dose-specific syringes, is designed to allow flexible, physician-guided dosing, particularly during the early stages of therapy. The company said this format is expected to offer a more cost-effective treatment option, with weekly therapy priced between Rs 325 and Rs 440. The pre-filled pen formulation offers the convenience of self-dosing for long-term use. Together, the two formats are intended to provide a structured treatment pathway that supports adherence, continuity of care, and improved patient outcomes. Alongside the product launch, Glenmark has introduced a patient support programme named 'Sankalp', aimed at assisting therapy initiation, improving comfort with injectable treatments, and supporting long-term adherence. Semaglutide, a GLP-1 receptor agonist, is widely used in the management of Type 2 diabetes, particularly in patients with comorbidities such as obesity, cardiovascular disease, heart failure with preserved ejection fraction (HFpEF), and chronic kidney disease, due to its broader cardiometabolic benefits beyond glycaemic control. Alok Malik, President and Business Head, India Formulations, Glenmark Pharmaceuticals, said, 'Affordability is one of the biggest barriers to initiating advanced diabetes therapy in India. With GLIPIQ, we are setting a new benchmark in affordability for GLP-1 therapy, with weekly treatment starting at Rs 325. The vial-based format enables us to offer a more affordable option while supporting clinically guided initiation and flexible dosing. Building on our experience in the GLP-1 category, including Lirafit' (Liraglutide), and supported by our 'Sankalp' program, we aim to help more patients access, initiate, and continue therapy over time.' Glenmark Pharmaceuticals is engaged in the business of development, manufacturing, and marketing of pharmaceutical products, both formulations and active pharmaceutical ingredients, to regulated and semi-regulated markets. Glenmark Pharmaceuticals reported a 15.9% jump in consolidated net profit to Rs 403.21 crore on a 17.8% increase in revenue from operations to Rs 3,888 crore in Q3 FY26 over Q3 FY25. Shares of Glenmark Pharmaceuticals rallied 3.94% to Rs 2,181.05 on the BSE. Powered by Capital Market - Live

The product has been deemed bioequivalent to Flonase Allergy Relief Nasal Spray, marketed by Haleon US Holding LLC. The approved spray will be distributed in the US by Glenmark Therapeutics Inc., USA. According to Nielsen syndicated data for the 52-week period ended March 3, 2026, the Flonase Allergy Relief Nasal Spray market recorded annual sales of approximately $384.7 million, indicating a sizeable opportunity for Glenmark in the OTC segment. Marc Kikuchi, President & Business Head, North America, said, 'We are excited to announce the recent approval of Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC). As the first approved nasal spray distributed by Glenmark Therapeutics Inc., USA in the OTC space, we look forward to bringing this quality over-thecounter solution to our customers when we launch in April 2026.' Separately, Glenmark Pharmaceuticals Inc., USA also announced the launch of Milnacipran Hydrochloride Tablets in strengths of 12.5 mg, 25 mg, 50 mg, and 100 mg. The product is the authorized generic version of Savella Tablets. As per IQVIA sales data for the 12-month period ending January 2026, the Savella tablets market generated annual sales of around $102.9 million. Marc Kikuchi, President & Business Head, North America said, 'We are excited to announce the launch of Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg, the authorized generic to Savella' Tablets. This launch further strengthens our commitment to bring to market quality and affordable alternatives for patients.' The dual developments underline Glenmark's strategic push to strengthen its presence across both OTC and prescription segments in North America. Glenmark Pharmaceuticals is engaged in the business of development, manufacturing, and marketing of pharmaceutical products, both formulations and active pharmaceutical ingredients, to regulated and semi-regulated markets. Glenmark Pharmaceuticals reported a 15.9% jump in consolidated net profit to Rs 403.21 crore on a 17.8% increase in revenue from operations to Rs 3,888 crore in Q3 FY26 over Q3 FY25. Shares of Glenmark Pharmaceuticals declined 2.03% to Rs 2,142.10 on the BSE. Powered by Capital Market - Live

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch of Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg. Glenmark's Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg is the authorized generic to Savella'2 Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg. According to IQVIA sales data for the 12-month period ending January 2026, the Savella' Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg market2 achieved annual sales of approximately $102.9 million. Powered by Capital Market - Live

The injection will be available in 15 mmol P / 22 mEq K per 5 mL and 45 mmol P / 66 mEq K per 15 mL single-dose vials, as well as 150 mmol P / 220 mEq K per 50 mL pharmacy bulk package vials. The product is bioequivalent and therapeutically equivalent to the reference listed drug from Fresenius Kabi. Distribution is expected to begin in March 2026. According to sales data from IQVIA, the Potassium Phosphates Injection market in the US recorded annual sales of about $50.7 million for the 12-month period ended January 2026. Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, 'We look forward to growing our portfolio of products within the institutional channel with the upcoming launch of Potassium Phosphates Injection USP, 15 mmol P / 22 mEq K per 5 mL and 45 mmol P / 66 mEq K per 15 mL Single-Dose Vials and 150 mmol P / 220 mEq K per 50 mL Pharmacy Bulk Package Vials. We continue to strengthen our commitment to bring quality and affordable alternatives to market for patients in need with each injectable launch.' Glenmark Pharmaceuticals is engaged in the business of development, manufacturing, and marketing of pharmaceutical products, both formulations and active pharmaceutical ingredients, to regulated and semi-regulated markets. Glenmark Pharmaceuticals, the company, reported a 15.9% jump in consolidated net profit to Rs 403.21 crore on a 17.8% increase in revenue from operations to Rs 3,888 crore in Q3 FY26 over Q3 FY25. Powered by Capital Market - Live

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the upcoming launch of Potassium Phosphates Injection USP, 15 mmol P / 22 mEq K per 5 mL and 45 mmol P / 66 mEq K per 15 mL Single-Dose Vials and 150 mmol P / 220 mEq K per 50 mL Pharmacy Bulk Package Vials. Glenmark's Potassium Phosphates Injection USP, 15 mmol P / 22 mEq K per 5 mL and 45 mmol P / 66 mEq K per 15 mL Single-Dose Vials and 150 mmol P / 220 mEq K per 50 mL Pharmacy Bulk Package Vials is bioequivalent and therapeutically equivalent to the reference listed drug, Potassium Phosphates Injection USP, 15 mmol P / 22 mEq K per 5 mL, 45 mmol P / 66 mEq K per 15 mL, and 150 mmol P / 220 mEq K per 50 mL of Fresenius Kabi [NDA 212832]. Glenmark will begin distribution in March 2026.Powered by Capital Market - Live

The company said the product has been determined by the USFDA to be bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Flovent HFA Inhalation Aerosol, 44 mcg, of GlaxoSmithKline (NDA ' 021433). Fluticasone propionate is indicated as an inhaler for the treatment and management of asthma by prophylaxis as well as inflammatory and pruritic dermatoses. Fluticasone propionate nasal spray is indicated for managing allergic and nonallergic rhinitis Glenmark has also been granted a Competitive Generic Therapy (CGT) designation for the product and has been recognised as the 'first approved applicant' under section 505(j)(5)(B)(v)(III) of the FD&C Act. With this approval, the company will be eligible for 180 days of CGT exclusivity upon commercial launch. The inhalation aerosol will be distributed in the United States by Glenmark Pharmaceuticals Inc., USA starting March 2026. The approval further strengthens Glenmark's respiratory portfolio in the US and underscores its commitment to expanding access to complex inhalation therapies. According to IQVIA sales data for the 12-month period ended January 2026, the Flovent HFA Inhalation Aerosol, 44 mcg market recorded annual sales of approximately $520.1 million. Marc Kikuchi, President & Business Head, North America said, 'receiving approval for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation marks an important milestone in strengthening our respiratory portfolio in the U.S. The CGT designation and first approved applicant status reflect the technical expertise and dedication of our teams in bringing complex inhalation therapies to market. We remain committed to improving access to quality and affordable respiratory treatments for patients and healthcare providers.' Glenmark Pharmaceuticals is engaged in the business of development, manufacturing, and marketing of pharmaceutical products, both formulations and active pharmaceutical ingredients, to regulated and semi-regulated markets. Glenmark Pharmaceuticals, the company, reported a 15.9% jump in consolidated net profit to Rs 403.21 crore on a 17.8% increase in revenue from operations to Rs 3,888 crore in Q3 FY26 over Q3 FY25. The counter dropped 4.07% to Rs 2,037 on the BSE.Powered by Capital Market - Live

Glenmark Specialty SA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation. Glenmark's Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation has been determined by the FDA to be bioequivalent and therapeutically equivalent1 to the reference listed drug (RLD), FloVent'2 HFA Inhalation Aerosol, 44 mcg of GlaxoSmithKline Intellectual Property Ltd. England (NDA - 021433). Glenmark has been granted a Competitive Generic Therapy (CGT) designation for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation and is the 'first approved applicant as defined in section 505(j)(5)(B)(v)(III) of the FD&C Act. Therefore, with this approval, Glenmark is eligible for 180 days of CGT exclusivity upon commercialization. Glenmark's Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA starting in March 2026. The approval further strengthens Glenmark's respiratory portfolio in the U.S. and underscores its commitment to expanding access to quality inhalation therapies. According to IQVIA sales data for the 12-month period ending January 2026, the FloVent' HFA Inhalation Aerosol, 44 mcg market3 achieved annual sales of approximately $520.1 million. Powered by Capital Market - Live

The said injection is bioequivalent and therapeutically equivalent to the reference listed drug, Sodium Phosphates Injection USP, 45 mM P/15 mL (3 mM P/mL), of Hospira, Inc. The company stated that the 15 mM P/5 mL and 150 mM P/50 mL presentations are expected to have the same therapeutic effect as the reference listed drug upon which the US Food and Drug Administration (FDA) relied as the basis for safety and effectiveness. The pharma company will begin distribution in April 2026. According to IQVIA sales data for the 12-month period ending December 2025, the Sodium Phosphates Injection USP, 15 mM P/5 mL, 45 mM P/15 mL and 150 mM P/50 mL (3 mM P/mL) Single-Dose Vials market2 achieved annual sales of approximately $66.8 million. Marc Kikuchi, president & business head, North America said, 'We look forward to the upcoming launch of Sodium Phosphates Injection USP, 15 mM P/5 mL, 45 mM P/15 mL and 150 mM P/50 mL (3 mM P/mL) Single-Dose Vials, strengthening our commitment to bring to market quality and affordable alternatives for patients, while also further expanding our portfolio of products within the institutional channel.' Glenmark Pharmaceuticals is engaged in the business of development, manufacturing, and marketing of pharmaceutical products, both formulations and active pharmaceutical ingredients, to regulated and semi-regulated markets. The company's consolidated net profit jumped 15.9% to Rs 403.21 crore on 17.8% increase in net sales to Rs 3888 crore in Q3 FY26 over Q3 FY25. The counter shed 0.20% to Rs 2,122.80 on the BSE.Powered by Capital Market - Live

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the upcoming launch of Sodium Phosphates Injection USP, 15 mM P/5 mL, 45 mM P/15 mL and 150 mM P/50 mL (3 mM P/mL) Single-Dose Vials. Glenmark's Sodium Phosphates Injection USP, 15 mM P/5 mL, 45 mM P/15 mL and 150 mM P/50 mL (3 mM P/mL) Single-Dose Vials is bioequivalent and therapeutically equivalent to the reference listed drug, Sodium Phosphates Injection USP, 45 mM P/15 mL (3 mM P/mL), of Hospira, Inc. [NDA 018892], with the 15 mM P/5 mL (3 mM P/mL) and 150 mM P/50 mL (3 mM P/mL) presentations expected to have the same therapeutic effect as that of the listed drug product upon which the FDA relied as the basis of safety and effectiveness. Glenmark will begin distribution in April 2026.Powered by Capital Market - Live

Glenmark Pharmaceuticals Ltd gained for a third straight session today. The stock is quoting at Rs 2107.3, up 1.07% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.12% on the day, quoting at 25452.6. The Sensex is at 82117.03, down 0.19%. Glenmark Pharmaceuticals Ltd has gained around 5.38% in last one month. Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has gained around 6.36% in last one month and is currently quoting at 23051.85, up 0.53% on the day. The volume in the stock stood at 3.37 lakh shares today, compared to the daily average of 4.7 lakh shares in last one month. The benchmark March futures contract for the stock is quoting at Rs 2115.8, up 0.94% on the day. Glenmark Pharmaceuticals Ltd is up 60.45% in last one year as compared to a 12.9% jump in NIFTY and a 14.71% jump in the Nifty Pharma index.The PE of the stock is 39.65 based on TTM earnings ending December 25.Powered by Capital Market - Live